Skip to main content
SpringerLink
Log in

ICER releases final report on TKI and PD-1 agents for NSCLC

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Comparative Effectiveness Public Advisory Council

Reference

  • Institute for Clinical and Economic Review. ICER Releases Final Report with Pricing and Coverage Implications for Treatment of Advanced Non-Small Cell Lung Cancer with TKI and PD-1 Drugs. Internet Document : 1 Nov 2016. Available from: URL: https://icer-review.org/announcements/nsclc-final-report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER releases final report on TKI and PD-1 agents for NSCLC. PharmacoEcon Outcomes News 765, 3 (2016). https://doi.org/10.1007/s40274-016-3488-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3488-0

Search

Navigation